Status:
COMPLETED
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Lead Sponsor:
University of Southern California
Conditions:
Autosomal Dominant Polycystic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an one-year open-label study to determine treatment efficacy and feasibility of a trial that uses open-label interventions in ADPKD patients.
Detailed Description
Polycystic Kidney Disease (PKD) is the most common genetic disease leading to End Stage Kidney Disease (ESKD), affecting between 1 in 500-1000 individuals from every ethnic group. The autosomal domina...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient voluntarily gives informed consent to participate in the study and signed study's IC and HIPAA.
- Patient is age 18 or older at the time of consent.
- If applicable, female of reproductive potential (Females who are successfully sterilized (surgical sterilization methods include hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (defined as amenorrhea for at least 12 consecutive months) are not considered to be of reproductive potential) must be non-pregnant (as confirmed by a urine pregnancy test at screening) and non-lactating, and agree:
- Either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or
- Use 2 medically acceptable, highly-effective forms of contraception for the duration of study, and at least 30 days after discontinuing study drug (highly-effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable), and barrier methods (such as a condom or diaphragm) when used with a spermicide.))
- Patients has ADPKD diagnosed by unified criteria using a combination of ultrasound results, genotyping and MRI as needed (1, 2). Kidney ultrasound is usually used for screening because it is safe, effective, and inexpensive. Diagnostic criteria are based upon whether the genotype is known. Disease severity varies between the different genotypes. The great majority of patients at risk for ADPKD are from families with an unknown genotype. This diagnosis will take place prior to recruitment / inclusion into the study.
- The following ultrasonographic criteria for the diagnosis of ADPKD are for at-risk patients from families of where the genotype is not known:
- If the patient is between 18 and 39 years of age, at least three unilateral or bilateral kidney cysts. The specificity and positive predictive value at this age-range is 100 percent. (sensitivity of 82 and 96 percent for individuals between 15 and 29 years and between 30 to 39 years of age, respectively).
- If the patient is 40 to 59 years of age, at least two cysts in each kidney (sensitivity, specificity, and positive predictive value of 90, 100, and 100 percent, respectively).
- Among individuals 60 years or older, at least four cysts in each kidney. (100 percent sensitivity and specificity).
- The above patients with estimated GFR ≥30 ml/min i.e. with stage 1-3b CKD
- Plasma bicarbonate ≤ 25 mMol/L
- Metabolic acidosis
- The patient agrees to immediately inform Investigator and research coordinator of any changes or planned changes in concomitant medication
- Exclusion Criteria
- Patients with known allergy or sensitive to Pravastatin or NaCitrate
- Acute coronary disease, liver disease, muscle disease, or a history of pulmonary edema
- Creatine Phospho Kinase (CPK) \> 2ULN (2.5 ULN in African Americans). Elevated creatine phosphokinase could be a marker of rhabdomyolysis, which is a potential side effect of pravastatin. In general, patients with African American ancestry can have higher normal level of CPK
- Patients with systemic disease that impacting kidney per Investigator's decision
- Patients with known unstable cerebral aneurysm per Investigator's decision
- Pregnancy or lactation, or patients who refuse to use recommended contraception methods
- Proteinuria \> 500 mg/day
- History of non-compliance of medication per Investigator's decision
- Patients with uncontrolled hypertension, edema, or development of severe MA as per Investigator's decision
- History of cancer
- History of liver disease: hepatic failure/shock, cirrhosis
- Current or planned use of any of prohibited concomitant medication
- Patients with history of nephrolithiasis
- Following medications prohibited at the time of enrollment and during the study and if the patient is started on these medications then the patient will be excluded from the study:
- rapamycin or its analogues
- tolvaptan
- spironolactone
- cimetidine and ketoconazole
- erythromycin
- cyclosporine
- gemfibrozil
- colchicine
- niacin (\>1 g/day)
- other lipid lowering medications in the class of statins
Exclusion
Key Trial Info
Start Date :
January 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2025
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04284657
Start Date
January 30 2019
End Date
August 4 2025
Last Update
August 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keck School of Medicine of University of Southern California
Los Angeles, California, United States, 90033